Cargando…
United we stand: Double targeting of CD79B and CD20 in diffuse large B‐cell lymphoma
Polatuzumab vedotin is antibody‐drug conjugate (ADC) targeting CD79B approved for the treatment of patients with relapsed/refractory diffuse large B‐cell lymphoma when given in combination with bendamustine and rituximab. The report by Kawasaki et al. provide hints on what might be happening in lymp...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804191/ https://www.ncbi.nlm.nih.gov/pubmed/35917107 http://dx.doi.org/10.1111/bjh.18384 |